Kidney transplant trial withdrawn before it began

NCT ID NCT02113891

Terminated Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated Jun 20, 2026 · Updated 28 times

Summary

This study aimed to test the drug eculizumab (Soliris) in kidney transplant recipients who had signs of early, hidden rejection. The goal was to see if blocking part of the immune system could prevent long-term damage. However, the trial was withdrawn before any participants were enrolled, so no conclusions can be drawn.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eculizumab (Soliris)

What this could lead to

If it had worked, this could point toward a treatment to prevent chronic kidney rejection in transplant patients.

What could go wrong

The trial was withdrawn before enrolling anyone, so no results exist. Eculizumab is expensive and carries risks like increased infections.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION